APA (7th ed.) Citation

S, M., BJ, W., YY, C., J, T., JR, A., DM, P., . . . DS, H. (2019). The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 125(2), 290. https://doi.org/10.1002/cncr.31770

Chicago Style (17th ed.) Citation

S, Malempati, et al. "The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy Is Feasible but Does Not Improve Outcome for Patients with Metastatic Rhabdomyosarcoma: A Report from the Children's Oncology Group." Cancer 125, no. 2 (2019): 290. https://doi.org/10.1002/cncr.31770.

MLA (9th ed.) Citation

S, Malempati, et al. "The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy Is Feasible but Does Not Improve Outcome for Patients with Metastatic Rhabdomyosarcoma: A Report from the Children's Oncology Group." Cancer, vol. 125, no. 2, 2019, p. 290, https://doi.org/10.1002/cncr.31770.